A Phase 2 interventional study of Dexamethasone and Placebo Vehicle in Dry Eye, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Ocular Therapeutix, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 6th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 4th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2015.
This study's enrollment of 43 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 36 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 16 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of dry eye disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
Drug: Dexamethasone
PV (placebo drug delivery vehicle)
Other: Placebo Vehicle
Total Corneal Fluorescein Staining
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)
Time frame: Day 15
Total Corneal Fluorescein Staining
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)
Time frame: Day 30
Total Conjunctival Lissamine Green Staining
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)
Time frame: Day 15
Total Conjunctival Lissamine Green Staining
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)
Time frame: Day 30
| Milestone | OTX-DP | Placebo Vehicle |
|---|---|---|
| Started | 22 | 21 |
| Completed | 20 | 19 |
| Not completed | 2 | 2 |
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Total Corneal Fluorescein Staining | 4.09 ± 2.671 | 5.05 ± 3.041 |
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Total Corneal Fluorescein Staining | 4.64 ± 2.361 | 6.38 ± 3.278 |
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Total Conjunctival Lissamine Green Staining | 4.36 ± 2.517 | 5.67 ± 4.199 |
National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Total Conjunctival Lissamine Green Staining | 6.41 ± 2.130 | 7.81 ± 3.642 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-DP | 0/22 (0%) | 1/22 (4.5%) | 15/22 (68.2%) |
| Placebo Vehicle | 0/21 (0%) | 0/21 (0%) | 11/21 (52.4%) |
| Event | OTX-DP | Placebo Vehicle |
|---|---|---|
| Myocardial infarctionCardiac disorders | 1/22 | 0/21 |
| Event | OTX-DP | Placebo Vehicle |
|---|---|---|
| Adverse EventsGeneral disorders | 15/22 | 11/21 |
| Age, Continuous(years) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Mean | 62.3 (41 to 84) | 62.5 (46 to 77) | 62.4 (41 to 84) |
| Sex: Female, Male(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Female | 13 | 17 | 30 |
| Male | 9 | 4 | 13 |
| Ethnicity (NIH/OMB)(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 20 | 20 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 21 | 20 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Iris Color(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Blue | 5 | 10 | 15 |
| Brown | 8 | 7 | 15 |
| Hazel | 7 | 3 | 10 |
| Green | 2 | 1 | 3 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2015 to primary completion in Aug 2015, 7 months.
Results were first posted in Mar 2018, 2 years 7 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 7 months is close to that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone